

# Birch Pollen Allergy - Pipeline Review, H2 2020

<https://marketpublishers.com/r/BAC18BF9B94EN.html>

Date: July 2020

Pages: 38

Price: US\$ 2,000.00 (Single User License)

ID: BAC18BF9B94EN

## Abstracts

Birch Pollen Allergy - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy - Pipeline Review, H2 2020, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Birch Pollen Allergy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1,

3, 2 and 2 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).

The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Birch Pollen Allergy - Overview
- Birch Pollen Allergy - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Birch Pollen Allergy - Therapeutics Assessment
- Assessment by Target
- Assessment by Route of Administration
- Assessment by Molecule Type
- Birch Pollen Allergy - Companies Involved in Therapeutics Development
- Anergis SA
- Biomay AG
- HAL Allergy BV
- Laboratorios LETI SL
- Polyrizon Ltd
- Regeneron Pharmaceuticals Inc
- Roxall Medizin GmbH
- S-TARget therapeutics GmbH
- Birch Pollen Allergy - Drug Profiles
- Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Allergen for Birch Pollen Allergy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- birch pollen allergen extract - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BM-31 - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress  
PL-102 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Birch Pollen Allergy - Dormant Projects  
Birch Pollen Allergy - Discontinued Products  
Birch Pollen Allergy - Product Development Milestones  
Featured News & Press Releases  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Birch Pollen Allergy, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Birch Pollen Allergy - Pipeline by Anergis SA, H2 2020

Birch Pollen Allergy - Pipeline by Biomay AG, H2 2020

Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2020

Birch Pollen Allergy - Pipeline by Laboratorios LETI SL, H2 2020

Birch Pollen Allergy - Pipeline by Polyrizon Ltd, H2 2020

Birch Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2020

Birch Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2020

Birch Pollen Allergy - Pipeline by S-TARget therapeutics GmbH, H2 2020

Birch Pollen Allergy - Dormant Projects, H2 2020

Birch Pollen Allergy - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Birch Pollen Allergy, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

### COMPANIES MENTIONED

Anergis SA

Biomay AG

HAL Allergy BV

Laboratorios LETI SL

Polyrizon Ltd

Regeneron Pharmaceuticals Inc

Roxall Medizin GmbH

S-TARget therapeutics GmbH

## I would like to order

Product name: Birch Pollen Allergy - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/BAC18BF9B94EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BAC18BF9B94EN.html>